Comparing effects of a long acting GLP-1 receptor agonist liraglutide with a short acting GLP-1 receptor agonist lixisenatide on diabetic cardiac autonomic neuropathy and glycemic variability evaluated by power spectral analysis of 24-hr heart rate and continuous glucose monitoring.
Not Applicable
Recruiting
- Conditions
- Type 2 diabetes
- Registration Number
- JPRN-UMIN000017144
- Lead Sponsor
- Department of Endocrinology and Metabolism, Dokkyo Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1)Type 1 diabetes 2)Liver dysfunction (hepatic enzymes more than three times the upper limit of normal ranges) 3)A pregnant woman and/or a woman under breast-feeding 4)Impaired kidney function (serum crearinine greater than 1.3 mg/dl in men, 1.2 mg/dl in women) 5)Diabetic proliferative retinopathy 6)The patients who has an anamnesis of hypersensitivity to the ingredient of a trial drug 7)Cigarette smokers
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Differences in 24-hr glycemic variability using continuous glucose monitoring systems , Differences in 24-hr heart rate variability evaluated by power spectral analysis Differences in 24-hr mean heart rate
- Secondary Outcome Measures
Name Time Method 24-hour blood pressure variability Gastric emptying rate by an acetaminophen loading test Orthostatic hypotension by Schellong test Plasma levels of A- and B-type natriuretic peptide (ANP and BNP) Serum 1, 5 anhidroglucitol (1, 5-AG) Safety evaluation